1 recruiting. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Hemimegalencephaly: new trials by email Literature Review of Hemimegalencephaly trials Research Report on Hemimegalencephaly
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Tolerability, and Pharmacokinetics of SVG103 (Paxalisib) in Focal Cortical Dysplasia Type II (FCD-II), Tuberous Sclerosis Complex (TSC) or Hemimegalencephaly (HME) SVG103 - Focal Cortical Dysplasia, Tuberous Sclerosis Complex (TSC) | Phase 1 / Phase 2 | Recruiting | Sovargen | 12 | 2026-07-14 | 2026-08-10 |
Focal Cortical Dysplasia (1) · Tuberous Sclerosis (1)
Congenital Abnormalities (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Craniofacial Abnormalities (1) · Genetic Diseases, Inborn (1) · Hamartoma (1) · Heredodegenerative Disorders, Nervous System (1) · Malformations of Cortical Development (1) · Malformations of Cortical Development, Group I (1) · Megalencephaly (1) · Musculoskeletal Abnormalities (1) · Musculoskeletal Diseases (1) · Neoplasms (1) · Neoplasms, Multiple Primary (1) · Neoplastic Syndromes, Hereditary (1) · Nervous System Diseases (1)
Sovargen (1)
Australia (1)